The PR does read like they only sold them one. In the past, they've used lanuage that implies they sold more than 1 unit.
It's not that big of a deal if they only sold them 1.
They know that they are lying... They don't really care.
I think that the clearest path forward will be to reduce the claim on the label and go after a smaller market/let doctors decide what the patient range should be. Show them the results, but tell them that the label indicates it should be used for patients who are on a lower dose. IMO, it would work well for people needing 12-16mg as well as those using 4-8mg.
The only thing the FDA can say is that they need to test it on the appropriate patient population... Which would be more of the same from them.
You're right... I'm the only one to feel this way. You're a jerk...We get it.
I used to think that you (all IDs included) could be persuaded, but it isn't going to happen. You've got your agenda. Have fun with that.
Reckitt Benckiser announced Tuesday the start of a strategic review of its pharmaceutical business, which the company said will include "all options for maximising value for our shareholders." CEO Rakesh Kapoor noted that although the unit is "a fantastic business...it’s not core to the company."
I'm no mentalist, but I do read and educate myself.
They've got no intention of developing that... He has made it pretty clear that they aren't a pharma company. It is also a known fact that the pharma business is up for sale.
This is lip service intended to attract a buyer.
The Deerfield deal was great... We got the money we needed to fund operations for 2 years (and run two trials) and they got a nice profit. Fanapt is a total bust, so it wasn't a huge profit, but it was one that one should expect when they loan a company the size of Titan 20 million dollars.
The warrants, priced at 1.25 were more than good for Titan.
They'll release the affidavit in a few days (the evidence they used to get the warrant). I doubt it has to do with Titan. It takes a lot of time to obtain enough evidence to get one of these warrants. More than a few months in a lot of cases.
There is a lot of potential downside... There is also a nice return to be had if things work out.
That is how biotechs work. To say there is no downside in a biotech in not a genuine, or informed, statement.
Can you post the part where it mentions other formulations? If it truly says other formulations (not products) I'll be happy to admit my fault.
Why can't you stick to one ID?
You've already admitted that you use multiple IDs, so what is the point? I can't keep up...
I know, I'm just asking them to post the things they are referring to... I don't think they can actually do it.
To be fair, the 5 million doesn't give us the ability to handle the trial and there is still not commitment from Braeburn to handle any additional trials... Though it seems more likely after this agreement.
You think you're clever, but your statement doesn't make any sense.
If 75% of the market uses the higher mg dose, why wouldn't Braeburn push it?
They're willing to exclude 75% of the market to pay a lower royalty?
Outside of that, it appears that "other products" actually relate to other products. Why else would it mention Braeburn purchasing a second product? Probuphine is one product and it has already been purchased. Licensing agreements aren't specific to dosage. They are specific to the product.
So if they start turning a profit (which seems likely), that isn't going to help?
No need to respond because you obviously have an agenda, but everyone knows your statement is ridiculous.
What is wrong with you and the two people who thought it was a good idea to give this post a thumbs up?
You deny reality with this stuff.